Seca GmbH & Co. Kg.
8
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Possibilities of Recording Changes in Various Health Parameters by Measuring Bioimpedance With the mBCA 555 During the Use of Products From the L112 Product Range
Role: collaborator
Generation of Prediction Equations for BIA of the Elderly
Role: lead
Comparing Medical Body Composition Analyzer Seca mBCA 555 With Seca mBCA 515
Role: lead
Generation of Prediction Equations to Analyze Body Composition of Obese Adults Based on BIA
Role: lead
Generation of Normal Ranges to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)
Role: lead
Generation of Prediction Equations to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)
Role: lead
Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)
Role: lead
Application and Adaption of Device Specific Body Composition Formulas to Various Ethnic Groups
Role: lead
All 8 trials loaded